May I say at the beginning, and my message is perhaps a slightly cryptic one, that both the NHS and medical science have a clear cut need for visionaries, but they also have a clear cut need for plumbers.
In 1948 a paper was published in the British Medical Journal describing the use of an antibiotic for the treatment of tuberculosis. The rationale was stated succinctly in the Introduction. The natural history of pulmonary tuberculosis is in fact so variable and unpredictable that evidence of improvement or cure following the use of a new drug in a few places cannot be accepted as proof of the effect of that drug. The history of chemotherapeutic trials in tuberculosis is filled with errors due to the empirical evaluation of drugs. The paper was the Medical Research Council trial of streptomycin in tuberculosis and this was the first randomized controlled trial to be reported in the history of medicine. A very bright statistician, Austin Bradford Hill had persuaded the Medical Research Council that more formal evaluation of that drug using randomization was actually required.
The subsequent history of the Health Service has been influenced substantially by clinical trials, most evident perhaps in the field where there have been some major public health triumphs. For example, cardiovascular disease; heart disease and strokes have fallen substantially in this country and most westernized societies over the last few years and with that there has been an increase in the number of cardiovascular outcome trials. Statistics too have moved on; powerful techniques of systematic review and Director, Research & Development, Department of Health meta-analysis have been introduced and scientifically there have been as many developments in clinical trial methodology as indeed in any other areas of medicine. In parallel with development of trial methodology we have seen radical and fundamental advances in science. To take, for instance, the field of drug development, the capacity of the pharmaceutical industry to create new compounds by combinatorial chemistry, and test them by new screening methods has resulted in a dramatic increase in the number of compounds screened. In the amount of time it would take to screen about 1000 compounds in 1970, today about 10 million compounds can be screened for biological activity which may be of therapeutic use.
From the point of the Health Service the effect has been equally dramatic. Post-1948 there has been a dramatic and exponential increase in the number of drugs which are available for treating patients. This does not come cheap. The cost of bringing a drug to the market place is approaching 500 million dollars per agent. Industry requires to recover those drug costs and the consequential costs to the Health Service increase equally exponentially. If one extrapolates to the burden of untreated disease, one sees the size of the problem if only a minority of those agents are actually successful. The prevalence figures for some of the diseases for which clinical trials are currently being undertaken illustrates this. Multiple sclerosis treatment with beta interferon costs about £10000/year and the prevalence rate is something like 60 000. The prevalence of rheumatoid arthritis is half a million patients. The biggest threat to human health of all-obesity has a prevalence of no less than 12.5 million. So we see here potentially an enormous opportunity and an enormous challenge. Now I am not arguing in any sense that evidence from scientific trials is going to resolve these issues. It is clearly not: it can in many ways make them more difficult. What I am saying is that, if there is to be a public debate about the funding of healthcare and the new technologies, that debate has to be informed with adequate scientific evidence based upon objective clinical trials. All this seems quite straightforward. However, I have concealed one little fact that I now want to develop. This is best illustrated by referring back again to that trial in 1948 of a new drug for treating tuberculosis. We all know the pattern of the incidence of tuberculosis, very good news until recently, extremely bad news over the last few years. The decline in tuberculosis between the mid 1850s, when it really reached its peak in this country, and recent years has been dramatic with an enormous fall in mortality rates. The interesting factor is that if one examines that fall in standard mortality ratio (SMR), 86% of it occurred before that trial was actually carried out and only 14% subsequently. In other words most of the fall occurred as a result of improvements in public health, in nutrition and lifestyle rather than in specific chemotherapy. This is not to underestimate the importance of chemotherapy, but it is I think a point relevant to the relationship between science and social policy.
Let us look at the broader picture. The relative underprivileged indigenous inhabitants of British India in the 1920s and Mexico in the 1930s showed a very poor life expectancy under 40 years, on average (Figure 1 ). In the more developed westernized societies, life expectancy has been much longer and that is reflected in the reduction in premature death. The Global Burden of Disease Project, of the World Health Organization and the World Bank has looked at reversible risk factors as causes of death. This is a Number of survivors 100000 80000 60000 40000 20000 0 world wide study, not confined to westernized societies. Again I suspect it will not surprise you that malnutrition comes top of the list in causes of premature death and tobacco use comes second. It does not need emphasizing that the role of the clinical trial in dealing with these problems has been fairly limited. Clinical trials clearly have taken place both in studies of nutrition and in tobacco use. However, much of the information which we have about the impact of malnutrition and tobacco use on disease is based upon cohort studies in epidemiology. Hypertension, comes fairly high on the list as a cause of premature death. Hypertension has been the subject of an enormous number of clinical trials and is the first of what you might call the obvious medical conditions which have responded enormously well to treatment.
Let us look at that a little more carefully because I think there is a very interesting lesson. If we look at a map of England showing the location of premature death from hypertension related disease the extraordinary factor is the variability with differences in the standardized mortality ratio of more than three-fold, between less than 60 and more than 173 with the worst areas in inner London, the North West and the North East which are the least prosperous regions. So there is no doubt whatsoever about a socioeconomic gradient here in what is to a large extent a reversible cause of premature death. You may well go on to say that this only shows that healthcare perhaps in these less prosperous regions is less good than the other regions and that something should be done about it.
Studies of the health of the Whitehall Civil Service population show that there is an enormous gradient between the well paid and the less well off. This is also seen in cardiovascular disease. There is also a gradient in blood pressure so that the lower socioeconomic groups have significantly higher blood pressures, small differences, but (1) Ultimate curve (2) New Zealand, [1934] [1935] [1936] [1937] [1938] [1939] [1940] [1941] (3) US, whies, [1939] [1940] [1941] (4) US, whites, 1929 -1931 (5) Italy, 1930 -1932 (6) US, whites, 1900 US, whites, -1902 & | (7) Japan, [1926] [1927] [1928] [1929] [1930] remember these are very large populations and highly significant. Does not this information simply confirm what I am saying, that the lower groups, the less well-off are getting less good, less adequate health care? Not entirely because when you look more closely at this you find that you are much more likely to be on antihypertensive drugs in the lower than in the higher socio-economic groups. In other words, if anything these people are getting more healthcare in the form of antihypertensive drugs, and yet their blood pressure is actually higher. So that it is not simply a matter of healthcare. The conventional biomedical measures of risk for coronary heart disease, such as smoking, cholesterol and blood pressure account for only a small proportion of the differences between the better off and the less well paid. The greater part of the difference in risk is unexplained but other studies have supported strongly the view that lifestyle control over your work and environment is a major player, which acts independently of those risk factors. There is, as it were, a social dimension to this disease as well as a medical dimension. This is not always matched by the sort of research which informs decision-making. If we look at 317 outcome trials conducted over the last 16 or 17 years in the field of cardiovascular disease, 301 of the 317 were actually drug trials, i.e. the impact of drugs on endpoints such as coronary heart disease and stroke. Only 16 of those dealt with diet or lifestyle and in some cases even those trials that dealt with lifestyle were actually combined at the same time with drug trials. There is a need for a broader pattern of medical research quite outwith the randomized controlled trial of drugs.
I would like to summarize what I have been saying, by using information from a recent lecture by Richard Sykes. What he says is this: that modern science has equipped us with some enormously powerful tools, for new drug development, combinatorial chemistry, high throughput screening and molecular genetics enabling greater and more effective targeting of disease. Further, we can look forward to post-genome physiology helping us to elucidate the processes of disease and therefore interact more effectively with medicine. This requires a broad scientific agenda if those advances are to be translated into social and professional decision-making in the management of populations, prevention of disease and individual professional judgement. This involves the inescapable questions about the funding of care and the implementation of scientific evidence. We have to bear in mind that most of the decisions for these chronic diseases I have discussed are actually made in primary care and not in hospital care, so we need to know much more about that; there is a public health agenda and last but not least the role of the patient and carer is becoming much more important.
I alluded to plumbers at the beginning of this talk and perhaps I can come back to the plumbers. The sort of scenario I have presented to you, that we need a programme of applied science as well as basic science to realize the complete scientific potential, is not unfamiliar in the university environment. In many cases there have been heated debates on the changes in the universities and strategies for research in the universities as we approach the next millennium. In one of our older universities this focused on a single problem and that was reducing the size of a large department of philosophy and at the same time it was proposed to develop applied engineering as a university topic. The philosophers, not surprisingly got up at the Senate meeting and one of them said what a tragedy for the university it was that the culture of philosophy was being replaced by the culture of the plumber. The response to him I think summarizes everything I have said in this presentation and everything you can say about the interaction of science in the health service. A society that does not reward excellence in plumbing because it is plumbing but does reward mediocre philosophy simply because it is philosophy will soon become a society in which neither its pipes nor its theories will hold water. 20 Volume 91 Supplement No. 36 1 9 9 8
